Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
After initial hemodynamic stabilization, 36 septic shock patients with heart rate > of 90 bpm
and requiring norepinephrine to maintain mean arterial pressure (MAP) more than 65 mmHg will
be randomised into two groups, esmolol group and control group. Patients allocated to esmolol
group will receive a continuous esmolol infusion to maintain a lowering of heart rate of 10%.
Norepinephrine will be titrated to achieve a MAP more than 65 mmHg. To investigate myocardial
performance, the investigators will assess Tissue Doppler imaging by echocardiography and
hemodynamic measures. Data will be obtained at baseline ,after esmolol infusion once achieved
the predefined heart rate threshold and 72hours after esmolol infusion.